tiprankstipranks
Trending News
More News >
Artelo Biosciences Inc (ARTL)
NASDAQ:ARTL
US Market
Advertisement

Artelo Biosciences (ARTL) AI Stock Analysis

Compare
527 Followers

Top Page

ARTL

Artelo Biosciences

(NASDAQ:ARTL)

Select Model
Select Model
Select Model
Underperform 34 (OpenAI - 4o)
Rating:34Underperform
Price Target:
Artelo Biosciences faces substantial financial hurdles with no revenue and continuous losses, heavily impacting its overall score. Technical indicators do not show a strong recovery trend, and the lack of new guidance from earnings calls further adds uncertainty. Valuation metrics are unfavorable due to negative earnings, making the stock less appealing to investors.
Positive Factors
Clinical Trial Progress
Successful Phase 1 trial results for ART26.12 indicate progress in drug development, potentially leading to future partnerships and revenue.
Low Financial Leverage
Low financial leverage provides Artelo with flexibility to raise capital without excessive debt burden, supporting long-term strategic initiatives.
Strategic Partnerships
Strategic partnerships can enhance R&D capabilities and market reach, potentially accelerating product development and commercialization.
Negative Factors
Continuous Losses
Ongoing losses without revenue generation highlight financial instability, limiting the company's ability to sustain operations without external funding.
Declining Assets and Equity
Declining assets and equity suggest weakening financial health, which could hinder long-term growth and investment in R&D.
Negative Cash Flows
Persistent negative cash flows indicate liquidity challenges, necessitating urgent financial restructuring to ensure business continuity.

Artelo Biosciences (ARTL) vs. SPDR S&P 500 ETF (SPY)

Artelo Biosciences Business Overview & Revenue Model

Company DescriptionArtelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
How the Company Makes MoneyArtelo Biosciences generates revenue primarily through the development and potential commercialization of its proprietary drug candidates. The company's revenue model is largely based on achieving clinical and regulatory milestones that can attract licensing deals or partnerships with larger pharmaceutical companies. These partnerships may result in upfront payments, milestone payments, and royalties on sales of successfully commercialized products. Artelo may also seek government grants or research funding to support its development programs. As a company focused on drug development, its earnings are contingent on successful clinical trials, regulatory approvals, and market adoption of its therapies.

Artelo Biosciences Financial Statement Overview

Summary
Artelo Biosciences faces significant financial challenges with continuous losses and no revenue generation. The low debt is a positive aspect, but declining assets and equity raise concerns about long-term sustainability. Cash flow issues further underscore the need for strategic financial management to improve its financial health.
Income Statement
15
Very Negative
Artelo Biosciences has consistently reported zero revenue, indicating no current commercial products. The company has a high negative EBIT and Net Income, reflecting continuous losses. The absence of revenue growth constrains its ability to improve financial performance in the short term.
Balance Sheet
30
Negative
The company maintains a low debt-to-equity ratio, which is favorable and indicates low financial leverage. However, there is a significant decline in total assets and stockholders' equity over time, suggesting potential financial instability.
Cash Flow
25
Negative
Artelo Biosciences shows negative operating and free cash flows, indicating cash burn. However, there was a positive cash flow from investing activities due to asset sales. The continuous negative cash flows highlight liquidity challenges.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.00
EBITDA-10.54M-10.11M-9.93M-10.29M-7.44M-4.71M
Net Income-10.50M-9.83M-9.29M-10.08M-7.44M-4.65M
Balance Sheet
Total Assets4.36M4.70M13.04M20.42M12.63M4.38M
Cash, Cash Equivalents and Short-Term Investments2.07M2.34M10.43M17.53M10.06M2.14M
Total Debt896.00K104.00K23.00K63.00K95.00K0.00
Total Liabilities5.76M1.84M1.29M1.02M593.00K502.18K
Stockholders Equity-1.41M2.86M11.75M19.40M12.04M3.87M
Cash Flow
Free Cash Flow-6.63M-8.35M-8.21M-8.01M-6.14M-4.35M
Operating Cash Flow-6.63M-8.35M-8.21M-8.01M-6.14M-4.35M
Investing Cash Flow4.44M7.77M3.51M2.96M-3.44M0.00
Financing Cash Flow3.13M112.00K567.00K0.0014.11M1.98M

Artelo Biosciences Technical Analysis

Technical Analysis Sentiment
Negative
Last Price4.76
Price Trends
50DMA
8.28
Negative
100DMA
8.83
Negative
200DMA
7.61
Negative
Market Momentum
MACD
-0.86
Negative
RSI
34.92
Neutral
STOCH
35.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARTL, the sentiment is Negative. The current price of 4.76 is below the 20-day moving average (MA) of 5.18, below the 50-day MA of 8.28, and below the 200-day MA of 7.61, indicating a bearish trend. The MACD of -0.86 indicates Negative momentum. The RSI at 34.92 is Neutral, neither overbought nor oversold. The STOCH value of 35.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ARTL.

Artelo Biosciences Risk Analysis

Artelo Biosciences disclosed 56 risk factors in its most recent earnings report. Artelo Biosciences reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Artelo Biosciences Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
55
Neutral
$385.92M-9.26-84.55%76.43%-35.66%
43
Neutral
$159.81M-2.7418.15%
37
Underperform
$3.20B-14.50-70.28%
37
Underperform
$50.49M-0.20-63.88%77.72%
35
Underperform
$18.09M-1.9322.63%
34
Underperform
$7.40M-356.46%4.49%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ARTL
Artelo Biosciences
4.76
-1.96
-29.17%
PALI
Palisade Bio
1.31
-2.25
-63.20%
GLMD
Galmed Pharmaceuticals
1.55
-3.18
-67.23%
INM
InMed Pharmaceuticals
2.22
-2.13
-48.97%
GLTO
Galecto
3.52
-8.32
-70.27%
SPRC
SciSparc Ltd.
6.03
1.41
30.52%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 22, 2024